A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans

A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans

Single molecules that combine complementary modes of action with glucagon-like peptide-1 receptor (GLP-1R) agonism are best-in-class therapeutics for obesity treatment. NN1706 (MAR423, RO6883746) is a fatty-acylated tri-agonist designed for balanced activity at GLP-1R and glucose-dependent insulinot...

Full description

Saved in:
Bibliographic Details
Main Authors: Brian Finan, Jonathan D. Douros, Ronald Goldwater, Ann Maria Kruse Hansen, Julie B. Hjerpsted, Karina Rahr Hjøllund, Martin K. Kankam, Patrick J. Knerr, Anish Konkar, Stephanie A. Mowery, Timo D. Müller, John Rømer Nielsen, Sune Boris Nygård, Diego Perez-Tilve, Kirsten Raun, Bin Yang, Matthias H. Tschöp, Richard D. DiMarchi
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Molecular Metabolism
Subjects:
Obesity
Incretins
Glucagon
Clinical
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877825000365
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2212877825000365

Similar Items